缬沙坦对原发性高血压患者血浆hs-CRP、ET-1以及NO含量的影响

目的观察血管紧张素受体拮抗剂缬沙坦治疗原发性高血压患者对血浆高敏C反应蛋白（hs—CRP）、内皮素1（ET-1）及一氧化氮（NO）的影响。方法92例原发性高血压患者服用缬沙坦80mr／d，连续治疗4周，于服药前后测定hs—CRP、NO、ET的血浆浓度。对比观察其浓度的变化。结果原发性高血压患者经缬沙坦治疗后血压均较治疗前显著下降（P〈0．05），同时可降低高血压患者血浆hs—CRP、ET-1含量，升高NO水平含量；观察组hs—CRP、ET-1下降水平及NO升高水平优于对照组（P〈0．05）。结论缬沙坦有效降压的同时可改善血管内皮功能，降低炎症反应。

Effects of valsartan on hypertension in patients with hs-CRP, ET-1 and NO content in

Objective Observation of angiotensin receptor blocker valsartan in patients with essential hypertension on plasma high-sensitivity C-reactive protein( hs-CRP), endothelin-1 ( ET-1 ) and nitric oxide(NO)effects. Methods 92 cases of essential hypertension patients treated with valsartan 80 mg/d, continuous treatment for 4 weeks, on medication before and after the determination of hs-CRP, NO, ET plasma concentrations.Comparative observation of its concentration changes. Results The effect of valsartan in patients with essential hypertension than those before treatment after treatment blood pressure decreased significantly( P ＜ 0.05 ), while lowering blood pressure in patients with hs-CRP, ET-1 levels,increased NO level content; Observer Group of hsCRP,ET-1 decreased levels and elevated levels of NO than the control group(P ＜0.05). Conclusion Valsartan can be an effective step-down at the same time improve endothelial function, reduce inflammatory response.